AngioDynamics posts Q1 FY2027 earnings beat and names new CEO
AngioDynamics reported fiscal 2027 first‑quarter net sales of $80.9 million, up 6.9% year‑over‑year, and an adjusted loss of $0.04 per share, beating the consensus loss of $0.11. GAAP loss was $0.17 per share on a $7.1 million net loss. The company reaffirmed its FY2027 revenue guidance of $336 million‑$341 million and adjusted‑loss guidance of $0.29‑$0.24 per share. Eric Honroth was appointed President and CEO, effective 2 Nov 2026, succeeding retiring founder Jim Clemmer.
Why it matters
The company’s beat and unchanged full‑year outlook keep the FY2027 guidance in place, so investors can rely on the $336‑$341 million sales range and the $0.29‑$0.24 adjusted‑loss range (the company says it expects these figures,). The CEO transition signals a leadership change that may affect future strategy, as noted in the press release ().
Key facts
- 1Net sales were $80.9 million, a 6.9% increase versus the prior‑year quarter. stocktitan.net
- 2Adjusted loss per share was $0.04. stocktitan.net
- 3GAAP loss per share was $0.17, representing a GAAP net loss of $7.1 million. stocktitan.net
- 4FY2027 revenue guidance was $336 million‑$341 million. rttnews.com
- 5Adjusted‑loss guidance for FY2027 was $0.29‑$0.24 per share. rttnews.com
- 6Eric Honroth will become President and CEO on 2 Nov 2026, succeeding Jim Clemmer. stocktitan.net
Summary written by AlphAI AI Desk from 20 of 23 sources. Not investment advice. Figures are as stated by the linked sources.